Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Lheureux

Showing results (21-30 of 144) with videos related to

Pageof 15
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 5, 2020
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairPanagiotis A Konstantinopoulos, Stephanie Lheureux, Kathleen N Moore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
DNA Methylation as a Robust Classifier of Epithelial Ovarian CancerCharles A Ishak, Stephanie Lheureux, Daniel D De Carvalho
Expert Opinion on Drug Safety|June 9, 2015
Safety evaluation of olaparib for treating ovarian cancerStephanie Lheureux, Valerie Bowering, Katherine Karakasis, et al.
Lancet (London, England)|March 27, 2019
Epithelial ovarian cancerStephanie Lheureux, Charlie Gourley, Ignace Vergote, et al.
Cancers|March 10, 2022
Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic CancersLawrence Kasherman, Shiru Lucy Liu, Katherine Karakasis, et al.
Gynecologic Oncology|June 15, 2015
Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for preventionStephanie Lheureux, Patricia A Shaw, Katherine Karakasis, et al.
Cancer|June 23, 2015
Ovarian cancer treatment: The end of empiricism?Stephanie Lheureux, Katherine Karakasis, Elise C Kohn, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 22, 2020
Adjuvant treatment in early stage cervical cancer-does more equal better?Ainhoa Madariaga, Lawrence Kasherman, Kathy Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2020
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020Ainhoa Madariaga, Luisa Bonilla, Michelle McMullen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 12, 2020
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse eventsAinhoa Madariaga, Valerie Bowering, Soha Ahrari, et al.
Pageof 15

Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 5, 2020
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairPanagiotis A Konstantinopoulos, Stephanie Lheureux, Kathleen N Moore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
DNA Methylation as a Robust Classifier of Epithelial Ovarian CancerCharles A Ishak, Stephanie Lheureux, Daniel D De Carvalho
Expert Opinion on Drug Safety|June 9, 2015
Safety evaluation of olaparib for treating ovarian cancerStephanie Lheureux, Valerie Bowering, Katherine Karakasis, et al.
Lancet (London, England)|March 27, 2019
Epithelial ovarian cancerStephanie Lheureux, Charlie Gourley, Ignace Vergote, et al.
Cancers|March 10, 2022
Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic CancersLawrence Kasherman, Shiru Lucy Liu, Katherine Karakasis, et al.
Gynecologic Oncology|June 15, 2015
Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for preventionStephanie Lheureux, Patricia A Shaw, Katherine Karakasis, et al.
Cancer|June 23, 2015
Ovarian cancer treatment: The end of empiricism?Stephanie Lheureux, Katherine Karakasis, Elise C Kohn, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 22, 2020
Adjuvant treatment in early stage cervical cancer-does more equal better?Ainhoa Madariaga, Lawrence Kasherman, Kathy Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2020
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020Ainhoa Madariaga, Luisa Bonilla, Michelle McMullen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 12, 2020
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse eventsAinhoa Madariaga, Valerie Bowering, Soha Ahrari, et al.
Pageof 15